Otonomy's ear infection drug succeeds in late-stage trial

[January 05, 2017]  (Reuters) - Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.

The drug, Otiprio, is approved for use in pediatric patients during tympanostomy tube placement surgery.

The company said it would submit a supplemental marketing approval application with the U.S. Food and Drug Administration in the first half of 2017.

(Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)

[© 2017 Thomson Reuters. All rights reserved.]

Copyright 2017 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.